DUBLIN, Sept. 27, 2016 /PRNewswire/ -- Perrigo
Company plc (NYSE: PRGO; TASE) today announced an exclusive
licensing agreement with Highland Pharmaceuticals, LLC for its
Tarex® methamphetamine ("meth") blocking technology and the
distribution rights of Zephrex-D® (pseudoephedrine HCI 30
mg). Zephrex-D® was developed using the Tarex® technology and
has been proven to be more than 98% effective at blocking one of
the more common domestic methods of illegal meth production.
This agreement is part of Perrigo's ongoing efforts in the fight
against meth drug abuse. Perrigo plans to integrate the Tarex®
technology into certain of its store brand and retailer own label
pseudoephedrine HCI products in the future and will immediately
begin distribution of Zephrex D® to its retail customers.
Perrigo's Executive Vice President & President, Consumer
Healthcare - Americas, Jeff Needham
commented that, "Across the country, illegal methamphetamine use
continues to be a significant issue. Our investment in Tarex®
technology is another example of Perrigo's commitment to help
protect and promote healthier communities. We are committed to
leveraging the Tarex® technology to extend our line of
meth-resistant pseudoephedrine products in the future."
About Perrigo
Perrigo Company plc, a top five global over-the-counter ("OTC")
consumer goods and pharmaceutical company, offers patients and
customers high quality products at affordable prices. From its
beginnings in 1887 as a packager of generic home remedies, Perrigo,
headquartered in Ireland, has
grown to become the world's largest manufacturer of OTC products
and supplier of infant formulas for the store brand market. The
Company is also a leading provider of generic extended topical
prescription products and receives royalties from Multiple
Sclerosis drug Tysabri®. Perrigo provides Quality Affordable
Healthcare Products® across a wide variety of product categories
and geographies primarily in North
America, Europe, and
Australia, as well as other
markets, including Israel,
China and Latin America. Visit Perrigo online at
(http://www.perrigo.com).
Forward-Looking Statements
Certain statements in this press release are "forward-looking
statements." These statements relate to future events or the
Company's future financial performance and involve known and
unknown risks, uncertainties and other factors that may cause the
actual results, levels of activity, performance or achievements of
the Company or its industry to be materially different from those
expressed or implied by any forward-looking statements. In some
cases, forward-looking statements can be identified by terminology
such as "may," "will," "could," "would," "should," "expect,"
"plan," "anticipate," "intend," "believe," "estimate," "predict,"
"potential" or the negative of those terms or other comparable
terminology. The Company has based these forward-looking statements
on its current expectations, assumptions, estimates and
projections. While the Company believes these expectations,
assumptions, estimates and projections are reasonable, such
forward-looking statements are only predictions and involve known
and unknown risks and uncertainties, many of which are beyond the
Company's control, including the timing, amount and cost of share
repurchases, future impairment charges, the ability to achieve its
guidance and the ability to execute and achieve the desired
benefits of announced initiatives. These and other important
factors, including those discussed under "Risk Factors" in the
Company's Form 10-KT for the six-month period ended December 31, 2015, as well as the Company's
subsequent filings with the SEC, may cause actual results,
performance or achievements to differ materially from those
expressed or implied by these forward-looking statements. The
forward-looking statements in this press release are made only as
of the date hereof, and unless otherwise required by applicable
securities laws, the Company disclaims any intention or obligation
to update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20120301/DE62255LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/perrigo-invests-in-tarex-patented-technology-as-a-key-investment-in-the-fight-against-methamphetamine-drug-abuse-300334729.html
SOURCE Perrigo Company plc